GASTROINTESTINAL STROMAL TUMOUR CANCER

House of Commons

As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.

Tabled 15 June 2015
2015-16 Session

That this House supports the aims of GIST Support UK, the key charity specifically focused on combating gastrointestinal stromal tumour (GIST); acknowledges that GIST is a rare and awful form of cancer commonly found in the digestive system; and calls on the Government to ensure that the only effective third-line drug that treats GIST, the Stivarga form of the drug Regorafenib, remains accessible to patients in England as it is in Scotland to ensure English patients are not second-class citizens.

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.